LARS: Impact of Early Postoperative Treatment With Posterior Tibial Nerve Stimulation on the Incidence and Duration of Low Anterior Rectal Resection Syndrome

Sponsor
Innovacion en Cirugía Vigo (Other)
Overall Status
Recruiting
CT.gov ID
NCT05368168
Collaborator
(none)
114
1
2
20.9
5.4

Study Details

Study Description

Brief Summary

The treatment of rectal cancer is currently based on surgical resection of the rectum with total excision of the mesorectum, associated with neoadjuvant radiochemotherapy.

Surgical resections with sphincter preservation are frequently (60% of cases) associated with problems related to intestinal and defecatory function, which together are called Anterior Resection Syndrome (ARS) with varying degrees of severity.

Among the different treatments the investigators find posterior tibial nerve stimulation, a simple and non-invasive technique, which is currently used.

The study aims to analyze whether postoperative posterior tibial nerve stimulation in patients undergoing low anterior resection of the rectum has an impact on the incidence and duration of low anterior resection syndrome (LARS) and therefore on the quality of life of patients undergoing this type of intervention.

Therefore, treatment with PNTS is currently established for the management of LARS symptoms. Given that a large percentage of patients operated on for rectal neoplasms will develop this syndrome, the investigators intend to apply this treatment before the onset of symptoms in patients at risk for LARS. It is also an intervention with a low rate of side effects, the benefit that the investigators can obtain from its preventive application is clearly superior to the risk of undergoing such treatment.

The investigators´ hypothesis is: Posterior tibial stimulation for 6 weeks post-operative of low anterior resection with anastomosis has a favorable impact by reducing the incidence and duration of ARS and improving the quality of life of patients undergoing anterior rectal resections for cancer.

Condition or Disease Intervention/Treatment Phase
  • Device: Posterior tibial nerve stimulation (PTNS)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
114 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Assignment to one group or the other will be randomized by a simple 1:1 randomization method through the CRF automatically and after hospital discharge. Double-blind masking will be performed (patients will not know to which group they belong and the investigator will not know to which group each patient is assigned). The only person aware of the outcome of the randomization will be the functional tests nurse, who will apply the PTNS treatment. Patients in both groups will be appointed in the same way in the functional testing office, although patients in group 2 will not receive PTNS, the tibial nerve puncture will be applied, they will be stimulated until they perceive the corresponding current and then the neurostimulator will be turned off so that they do not receive the treatment.
Primary Purpose:
Treatment
Official Title:
Impact of Early Postoperative Treatment With Posterior Tibial Nerve Stimulation on the Incidence and Duration of Low Anterior Rectal Resection Syndrome
Actual Study Start Date :
Jun 3, 2022
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1: Posterior tibial nerve stimulation (PTNS)

Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization, WILL BE treated with posterior tibial nerve stimulation.

Device: Posterior tibial nerve stimulation (PTNS)
Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions). The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy.
Other Names:
  • Transcutaneous neurostimulator (Urgent PC)
  • No Intervention: Group 2: Standard of care

    Patients operated on at the Hospital Álvaro Cunqueiro for rectal neoplasia with anastomosis below 10 cm and who, after randomization,WILL NOT BE treated with posterior tibial nerve stimulation.

    Outcome Measures

    Primary Outcome Measures

    1. Efficacy of PTNS (Posterior Tibial Nerve Stimulation) treatment on the incidence and duration of RAS symptoms in patients undergoing anterior rectal resection with sphincter-sparing surgery. [12 months]

      Variables: Age (years), Sex (F/M), Gestation (Y/N), Births (Y/N), Tumor location (cm from anus), Radiotherapy (Y/N), Radiotherapy regimen (short/long), Neoadjuvant chemotherapy (Y/N), Surgical approach (open, laparoscopic,transanal/converted), Distance between anus and anastomosis (cm), Type of anastomosis (colorectal, coloanal, mechanical, manual, term-terminal, term-lateral), Performance of derivative stoma (Y/N), Extent of mesorectal excision (total/partial), Postoperative dehiscence (Y/N), Postoperative abdominal collection(Y/N). Postoperative bleeding (Y/N), Clavien-dindo classification. Time from surgery to stoma closure (months), sphincter disruption (Y/N), Manometry (mmHg), neurostimulation parameters: stimulation intensity (mA), foot (right/left), stimulus (sensitive/motor/both). LARS score (0-42)

    2. Impact of PTNS on the quality of life (EORTC-QLQ C30) [12 months]

      To evaluate the impact of PTNS on the quality of life of patients undergoing anterior rectal resection with sphincter-sparing surgery (as assessed by the EORTC-QLQ C30 quality of life questionnaire). The "European organization for reseach and treatment of cáncer quality life questionnaire core 30" (EORTC-QLQ C30) is a cancer-specific, multidimensional questionnaire comprising 30 items on five scales (physical, functional, emotional, cognitive, social), three items on symptoms (fatigue, nausea/vomiting, pain), six single-item items (constipation, diarrhea, hyporexia, insomnia, dyspnea,economic difficulties) and others on a global state of health. The score is between 1 and 100, where the higher the score, the greater the decrease in quality of life.

    Secondary Outcome Measures

    1. LARS Scale [12 months]

      To evaluate continence and number of stools (assessed by the LARS scale) in patients undergoing anterior rectal resection. "Low Anterior Resection Score" LARS scale is a quantitative variable of anterior resection syndrome related to quality of life. The scale ranges from 0 to 42 points with the highest score being a worsening result and it is categorized into 3 groups: no LARS (0-20 points), minor LARS (21-29 points) and major LARS (30-42 points).

    2. Impact of PTNS on the quality of life (EORTC-QLQ C29) [12 months]

      To evaluate sexual dysfunction in patients undergoing anterior rectal resection (assessed by the European Organization for Research and Treatment of Cancer-Quality of Life Questionnaires: EORTC-QLQ C29). The "European organization for reseach and treatment of cáncer quality life questionnaire core 29" (EORTC-QLQ C29) is a questionnaire specific to patients with rectal neoplasms. It comprises 19 questions common to all patients, four questions on female or male sexual dysfunction and seven questions for patients with or without stoma. The score is between 1 and 136, where the higher the score, the greater the decrease in quality of life.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients undergoing elective surgery (scheduled, non-urgent) who underwent anterior rectal resection or transit reconstruction with low anastomosis (below 10 cm from the anal margin) at the Hospital Álvaro Cunqueiro in Vigo after the start date of the study.

    • Anastomotic tightness (absence of dehiscence).

    • Patients older than 18 years old.

    • Acceptance to participate in the study.

    Exclusion Criteria:
    • Inability to understand the study instructions and recommendations.

    • Dementia or any type of mental disability.

    • Palliative surgery.

    • Patients with pacemakers.

    • Anti-coagulated patients.

    • Patients with trophic lesions on the skin of the ankles.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Álvaro Cunqueiro Vigo Pontevedra Spain 36213

    Sponsors and Collaborators

    • Innovacion en Cirugía Vigo

    Investigators

    • Study Director: Raquel Sánchez Santos, PhD, Complejo Hospitalario Universitario de Vigo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Innovacion en Cirugía Vigo
    ClinicalTrials.gov Identifier:
    NCT05368168
    Other Study ID Numbers:
    • LARS
    First Posted:
    May 10, 2022
    Last Update Posted:
    Jun 6, 2022
    Last Verified:
    Jun 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 6, 2022